BPC-157 Research Guide: Mechanism, Angiogenesis & Tissue-Repair Data (Australia)

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide, a chain of 15 amino acids, derived from a naturally occurring protein found in gastric juice. First isolated from human gastric secretions, BPC-157 has been the subject of extensive preclinical research since the 1990s, primarily by Croatian researcher Professor Predrag Sikirić and colleagues at the University of Zagreb.

The "stable gastric pentadecapeptide" description is more than a label: BPC-157 demonstrates notable stability in both acidic (gastric) and aqueous environments, a property unusual among research peptides and one that has shaped how it is studied. Its origin in gastric juice and its resistance to degradation in low-pH conditions are the defining structural facts that distinguish BPC-157 from most other tissue-repair peptides.

BPC-157's research interest centres on a small set of well-characterised mechanisms. Understanding these is what separates BPC-157 from the broader pool of "tissue repair" peptides:

• Angiogenesis via VEGF, the most consistently reported mechanism. BPC-157 appears to upregulate vascular endothelial growth factor (VEGF) expression, promoting the formation of new blood vessels. Because new vasculature is a rate-limiting step in repairing tendon, ligament and gut tissue, this angiogenic action is considered central to the peptide's observed effects across multiple tissue types.
• The nitric oxide (NO) system, BPC-157 has been studied for its modulation of the nitric oxide pathway, which governs vascular tone and blood flow. Interaction with the NO system is one of the proposed routes by which the peptide supports perfusion at an injury site.
• Growth-factor receptor expression in fibroblasts, preclinical work has examined BPC-157's upregulation of growth hormone receptor expression in tendon fibroblasts, a plausible link between the peptide and the tendon-healing outcomes reported in animal models.

The throughline across these mechanisms is vascular and local-repair signalling: BPC-157 is studied less as a systemic growth driver and more as a localised "create the conditions for repair" compound, building blood supply and recruiting repair machinery at the site of damage.

BPC-157 has been studied across a broad range of biological processes in preclinical (animal and in-vitro) models. The strongest and most frequently cited research areas are:

• Soft tissue repair, multiple studies in rodent models have demonstrated accelerated healing of tendons, ligaments, and muscle tissue. A frequently cited study showed complete quadriceps muscle-to-bone reattachment in rats treated with BPC-157, an outcome not replicated with any other known pharmacological intervention.
• Gastrointestinal health, consistent with its gastric origin, BPC-157 has shown cytoprotective effects on gastric mucosa, with research examining its role in gastric ulcer healing, inflammatory bowel conditions, and gut permeability.
• Bone healing, studies have examined BPC-157 in models of fracture repair and bone remodelling, an extension of the same angiogenesis-led repair mechanism.
• Neurological function, preclinical models have investigated effects on dopaminergic and serotonergic pathways, with potential implications for mood and neuroprotection research.

It is important to note that the majority of BPC-157 research to date is preclinical. No large-scale human clinical trials have been completed as of 2025, though the compound has attracted increasing pharmaceutical interest. Researchers should treat the tendon, ligament, gut and bone findings as animal-model and in-vitro evidence, not human-validated outcomes.

Tendon and ligament tissue is notoriously slow to heal because it is poorly vascularised, blood supply, not cellular activity, is often the limiting factor. This is precisely why BPC-157's angiogenic profile has made it a focus of musculoskeletal research: a compound that promotes new blood vessel formation at the injury site directly addresses the bottleneck in connective-tissue repair.

In the published rodent literature, the strongest BPC-157 musculoskeletal data comes from subcutaneous or intramuscular administration, the injectable lyophilised route. Researchers replicating these protocols typically use the reconstituted injectable form because that is the delivery method the source studies used. (For a dedicated treatment of whether oral/tablet BPC-157 is research-equivalent, see the section below.)

Research-grade BPC-157 is supplied as lyophilised powder in 3mL glass vials. The lyophilised content varies by strength, common options include 5mg, 10mg, and 20mg per vial. OzPeps currently stocks BPC-157 in 20mg vials; check the product page for current availability across strengths.

Reconstituting a 20mg vial with 2mL bacteriostatic water yields a 10mg/mL (10,000mcg/mL) working solution. Lyophilised BPC-157 is stable at −20°C for 24+ months. Once reconstituted, store at 2–8°C and use within 30 days. BPC-157's acid stability makes it one of the more forgiving peptides to dissolve, it goes into solution readily and tolerates handling better than longer, more fragile peptide chains. Use the OzPeps reconstitution calculator to prepare target concentrations for any vial strength, and the peptide reconstitution & storage guide for full step-by-step handling.

BPC-157's gastric stability raises an obvious question: can it work orally, or is injection required? The short answer is that it depends entirely on what is being studied, gut-targeted research and systemic tissue-repair research give different answers, and not all oral formulations are equivalent.

Rather than duplicate that analysis here, this monograph defers to the dedicated treatment: see the BPC-157 oral tablets vs injectable research guide → for the bioavailability evidence, the arginate-salt formulation nuance, and why delivery method matters for research integrity.

BPC-157 is frequently studied alongside complementary regenerative compounds, most commonly TB-500, and within multi-compound blends that pair it with GHK-Cu. Because the combined research rationale, per-compound mechanisms and blend reconstitution are covered in depth elsewhere, this page does not repeat them.

For the BPC-157 + TB-500 + GHK-Cu stacking rationale and the GLOW 70 blend, see the BPC-157 + TB-500 stack research guide →. OzPeps also stocks each compound individually, browse the full product catalogue.

BPC-157 is widely available from Australian research peptide suppliers. Quality indicators to look for:

• Lyophilised formulation (not pre-mixed solution, which degrades faster)
• Local Australian fulfilment for faster delivery
• Transparent product information including molecular weight and sequence

OzPeps supplies research-grade BPC-157 with fast Australia-wide shipping and discreet packaging. View BPC-157 stock and pricing →

All BPC-157 products are sold strictly for in-vitro laboratory and research purposes only. Not TGA-approved. Not for human or animal consumption. Researchers are responsible for all applicable regulatory compliance.